Status:
RECRUITING
Sympathetic Neurovascular Transduction: Role of Adrenergic Receptors and Sex Differences
Lead Sponsor:
University of Alberta
Conditions:
Vasoconstriction
Vasodilation
Eligibility:
All Genders
18-40 years
Phase:
PHASE4
Brief Summary
The main purpose of this interventional study is to examine differences in resting blood pressure control between healthy males and females. The main questions it aims to answer are: 1. Are there sex...
Detailed Description
Blood pressure is in part regulated by activity of your sympathetic nervous system (also known as your "fight or flight" response). Sympathetic nerve activity affects the size of your blood vessels, w...
Eligibility Criteria
Inclusion
- Between ages 18-40 years
- No diagnosed medical history of cardiovascular, respiratory, nervous system, or metabolic disease.
- Females must be pre-menopausal.
- Prior to study visit: abstained from caffeine, alcohol, strenuous exercise, and medication not taken regularly for at least 12 hours.
Exclusion
- Current diagnosis of cardiovascular, respiratory, nervous system, or metabolic disease that may impact blood pressure regulation. This will be assessed on a case-by-case basis by the study physician.
- Participants with bleeding or clotting disorders, or those currently taking blood thinners.
- Participants currently taking beta-agonist inhalers i.e. Ventolin (at least not in the last 24 hours).
- Females who are pregnant, confirmed by a pregnancy test.
- Females who have are less than 1 year postpartum or are breastfeeding.
- Females who are post-menopausal.
- Participants that are classified as obese (body mass index \> 30 kg ⋅ m2).
- Have a history of smoking regularly in the last 6 months (but nicotine substitutes (i.e. patch, gum) are not an exclusion criteria).
- Those with a known allergy to sulfites, or other components of the supplied solution of study drugs.
- Participants taking medications that are contraindicated with any of the study drugs, such as monoamine oxidase (MAO) inhibitors or tricyclic antidepressants.
- Participants who have not adhered to the pre-testing guidelines related to diet, alcohol or exercise will not be excluded, but will be rescheduled for a different day. This is to reduce experimental variability.
Key Trial Info
Start Date :
October 31 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05997732
Start Date
October 31 2023
End Date
December 1 2027
Last Update
January 8 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alberta
Edmonton, Alberta, Canada, T6G 2R3